Clinical trials: Fracture, Ankle

Deep Venous Thrombosis

Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

• Unknown status
• Age: 18 to 85 years

1. The use of LMWH following open reduction and internal fixation of ankle fractures will reduce the number of thrombi formed. 2. The rates of clinically significant DVT will be equivalent between two groups.

Trial name

NCT01029821

Testing

Low-Molecular-Weight Heparin

Where

United States

Volunteers

100 people, healthy volunteers welcome

Sponsor

University of Tennessee